[go: up one dir, main page]

RS60582B9 - Aril i heteroaril kondenzovani laktami - Google Patents

Aril i heteroaril kondenzovani laktami

Info

Publication number
RS60582B9
RS60582B9 RS20200917A RSP20200917A RS60582B9 RS 60582 B9 RS60582 B9 RS 60582B9 RS 20200917 A RS20200917 A RS 20200917A RS P20200917 A RSP20200917 A RS P20200917A RS 60582 B9 RS60582 B9 RS 60582B9
Authority
RS
Serbia
Prior art keywords
aryl
heteroaryl fused
fused lactams
lactams
heteroaryl
Prior art date
Application number
RS20200917A
Other languages
English (en)
Inventor
Martin Paul Edwards
Robert Arnold Kumpf
Pei-Pei Kung
Indrawan James Mcalpine
Sacha Ninkovic
Eugene Yuanjin Rui
Scott Channing Sutton
John Howard Tatlock
Martin James Wythes
Luke Raymond Zehnder
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of RS60582B1 publication Critical patent/RS60582B1/sr
Publication of RS60582B9 publication Critical patent/RS60582B9/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20200917A 2012-12-21 2013-12-05 Aril i heteroaril kondenzovani laktami RS60582B9 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21
EP17206218.4A EP3339303B9 (en) 2012-12-21 2013-12-05 Aryl and heteroaryl fused lactams

Publications (2)

Publication Number Publication Date
RS60582B1 RS60582B1 (sr) 2020-08-31
RS60582B9 true RS60582B9 (sr) 2021-09-30

Family

ID=49917684

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20200917A RS60582B9 (sr) 2012-12-21 2013-12-05 Aril i heteroaril kondenzovani laktami
RS20180103A RS56815B1 (sr) 2012-12-21 2013-12-05 Aril i heteroaril-fuzionisani laktami

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20180103A RS56815B1 (sr) 2012-12-21 2013-12-05 Aril i heteroaril-fuzionisani laktami

Country Status (47)

Country Link
US (3) US9040515B2 (sr)
EP (2) EP3339303B9 (sr)
JP (1) JP5909308B2 (sr)
KR (1) KR101712441B1 (sr)
CN (1) CN104870435B (sr)
AP (1) AP2015008574A0 (sr)
AR (1) AR094174A1 (sr)
AU (1) AU2013365908C1 (sr)
BR (1) BR112015014678B1 (sr)
CA (1) CA2893339C (sr)
CL (1) CL2015001733A1 (sr)
CR (2) CR20200273A (sr)
CU (1) CU24414B1 (sr)
CY (2) CY1119883T1 (sr)
DK (2) DK3339303T3 (sr)
DO (1) DOP2015000157A (sr)
EA (1) EA028317B1 (sr)
EC (1) ECSP15031579A (sr)
ES (2) ES2658974T3 (sr)
GE (1) GEP201706718B (sr)
GT (1) GT201500190A (sr)
HK (1) HK1208866A1 (sr)
HR (2) HRP20180060T1 (sr)
HU (2) HUE038238T2 (sr)
IL (1) IL239520B (sr)
LT (2) LT3339303T (sr)
MA (1) MA38175B1 (sr)
MD (1) MD4664C9 (sr)
ME (2) ME03793B (sr)
MX (2) MX2015008058A (sr)
MY (2) MY176307A (sr)
NO (1) NO2961649T3 (sr)
NZ (1) NZ708801A (sr)
PE (1) PE20151090A1 (sr)
PH (1) PH12015501367B1 (sr)
PL (2) PL3339303T3 (sr)
PT (2) PT3339303T (sr)
RS (2) RS60582B9 (sr)
SG (1) SG11201504076XA (sr)
SI (2) SI2935238T1 (sr)
TN (1) TN2015000281A1 (sr)
TR (1) TR201802791T4 (sr)
TW (1) TWI546293B (sr)
UA (1) UA111305C2 (sr)
UY (2) UY35225A (sr)
WO (1) WO2014097041A1 (sr)
ZA (1) ZA201504437B (sr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP2935303B1 (en) 2012-12-21 2021-02-17 Janssen BioPharma, Inc. 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EA031892B1 (ru) * 2014-06-17 2019-03-29 Пфайзер Инк. Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2
WO2015193768A1 (en) * 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
CN107148419A (zh) * 2014-10-28 2017-09-08 葛兰素史密斯克莱知识产权(第2 号)有限公司 Zeste增强子同源物2抑制剂
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
EP3236962A2 (en) 2014-12-23 2017-11-01 University of Copenhagen Treatment of cancer by inhibiting ezh2 activity
EP3683213B1 (en) * 2015-03-27 2022-10-12 Syngenta Participations Ag Intermediate for the preparation of microbiocidal heterobicyclic derivatives
UY36758A (es) * 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
PL3378859T3 (pl) 2015-11-19 2020-04-30 Jiangsu Hengrui Medicine Co., Ltd. Pochodna benzofuranu, sposób jej wytwarzania i jej zastosowanie w medycynie
AU2017260854B2 (en) 2016-05-05 2020-01-30 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
WO2018086589A1 (zh) * 2016-11-11 2018-05-17 上海海雁医药科技有限公司 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
RU2762893C2 (ru) 2017-05-18 2021-12-23 Цзянсу Хэнжуй Медсин Ко., Лтд. Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли
BR112019021023A2 (pt) 2017-05-18 2020-05-05 Jiangsu Hengrui Medicine Co cristal de base livre de derivado de benzofurano e método de preparação.
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
JP7201400B2 (ja) 2017-11-14 2023-01-10 ファイザー・インク Ezh2阻害剤組合せ療法
PT4043466T (pt) 2018-01-31 2024-10-14 Mirati Therapeutics Inc Inibidores de prc2
CN112533581B (zh) * 2018-06-07 2024-08-30 密歇根大学董事会 Prc1抑制剂及用其进行治疗的方法
CN112399857A (zh) 2018-07-09 2021-02-23 盲人庇护基金会 Prc2亚单位的抑制治疗眼失调
WO2020086857A1 (en) * 2018-10-24 2020-04-30 Vanderbilt University Wdr5 inhibitors and modulators
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR102689665B1 (ko) * 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
CA3165787C (en) * 2020-08-13 2023-06-06 Seung Hyun Jung Novel dioxoloisoquinolinone derivatives and use thereof
CN116457348B (zh) * 2021-02-26 2024-11-26 南京迈晟科技有限责任公司 Ezh2抑制剂及其用途
WO2024126650A1 (en) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Novel bicyclic-carboxamide compounds useful as pesticides
CN118978498A (zh) * 2024-10-22 2024-11-19 浙江雅辰药物科技股份有限公司 一种5-羟甲基四氢呋喃-3-醇的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US20070093515A1 (en) 2005-08-16 2007-04-26 Arrington Mark P Phosphodiesterase 10 inhibitors
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
LT2566327T (lt) 2010-05-07 2017-05-25 Glaxosmithkline Llc Indolai
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2681216B1 (en) * 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
WO2013049770A2 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
EP2935303B1 (en) 2012-12-21 2021-02-17 Janssen BioPharma, Inc. 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
EP2934567B9 (en) 2012-12-21 2018-08-22 Sanofi Exendin-4 derivatives as dual glp1/gip- or trigonal glp1/gip/glucagon agonists
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
MX358684B (es) 2012-12-21 2018-08-31 Hoffmann La Roche Peptidos como agonistas de oxitocina.
PL3608325T3 (pl) 2012-12-21 2022-11-07 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
BR112015014590B1 (pt) 2012-12-21 2022-12-20 Epizyme, Inc Composto, composição farmacêutica e estojo ou farmacêutico empacotado
LT2935248T (lt) 2012-12-21 2018-04-10 Plexxikon Inc. Kinazės moduliavimo junginiai ir būdai bei indikacijos
EA031892B1 (ru) 2014-06-17 2019-03-29 Пфайзер Инк. Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2

Also Published As

Publication number Publication date
CN104870435A (zh) 2015-08-26
BR112015014678A2 (pt) 2017-07-11
NZ708801A (en) 2018-08-31
PL2935238T3 (pl) 2018-05-30
HUE050009T2 (hu) 2020-11-30
PE20151090A1 (es) 2015-08-07
US9040515B2 (en) 2015-05-26
BR112015014678B1 (pt) 2021-12-07
MA38175A1 (fr) 2018-08-31
KR20150100823A (ko) 2015-09-02
PH12015501367B1 (en) 2018-08-03
PT3339303T (pt) 2020-07-30
US20140179667A1 (en) 2014-06-26
LT3339303T (lt) 2020-09-10
ES2808987T9 (es) 2021-11-29
KR101712441B1 (ko) 2017-03-07
HK1208866A1 (en) 2016-03-18
CL2015001733A1 (es) 2015-10-23
AU2013365908C1 (en) 2018-01-25
CR20200273A (es) 2020-09-23
ES2808987T3 (es) 2021-03-02
GEP201706718B (en) 2017-08-10
EA201590879A1 (ru) 2015-12-30
HUE038238T2 (hu) 2018-10-29
EP2935238B1 (en) 2017-12-27
TWI546293B (zh) 2016-08-21
EP3339303B1 (en) 2020-06-24
MX2020002924A (es) 2020-07-22
GT201500190A (es) 2016-01-21
AR094174A1 (es) 2015-07-15
JP5909308B2 (ja) 2016-04-26
AP2015008574A0 (en) 2015-07-31
PL3339303T3 (pl) 2021-01-25
SI2935238T1 (en) 2018-04-30
US10246433B2 (en) 2019-04-02
ZA201504437B (en) 2016-07-27
UA111305C2 (uk) 2016-04-11
DK3339303T3 (da) 2020-08-10
EP2935238A1 (en) 2015-10-28
MD20150052A2 (ro) 2015-12-31
IL239520B (en) 2018-05-31
AU2013365908A1 (en) 2015-06-11
HRP20201194T2 (hr) 2021-09-17
IL239520A0 (en) 2015-08-31
UY38712A (es) 2020-06-30
SG11201504076XA (en) 2015-06-29
TR201802791T4 (tr) 2018-03-21
MX2015008058A (es) 2015-10-30
CY1123237T1 (el) 2021-10-29
SI3339303T1 (sl) 2020-09-30
ECSP15031579A (es) 2017-08-31
CR20150279A (es) 2015-09-03
US20170233368A1 (en) 2017-08-17
PT2935238T (pt) 2018-02-09
WO2014097041A1 (en) 2014-06-26
CY1119883T1 (el) 2018-06-27
RS56815B1 (sr) 2018-04-30
MD4664B1 (ro) 2019-12-31
CA2893339C (en) 2017-06-13
ES2658974T3 (es) 2018-03-13
ME03793B (me) 2021-04-20
CN104870435B (zh) 2016-12-07
EA028317B1 (ru) 2017-11-30
RS60582B1 (sr) 2020-08-31
CU20150062A7 (es) 2015-11-27
EP3339303A1 (en) 2018-06-27
TW201446753A (zh) 2014-12-16
CU24414B1 (es) 2019-05-03
JP2016507497A (ja) 2016-03-10
CA2893339A1 (en) 2014-06-26
TN2015000281A1 (fr) 2016-10-03
ME02980B (me) 2018-10-20
LT2935238T (lt) 2018-02-26
NO2961649T3 (sr) 2018-02-17
DOP2015000157A (es) 2015-11-30
HRP20201194T1 (hr) 2020-11-13
DK2935238T3 (en) 2018-01-22
US20150175572A1 (en) 2015-06-25
MY176307A (en) 2020-07-28
PH12015501367A1 (en) 2015-09-02
AU2013365908B2 (en) 2017-07-20
MD4664C9 (ro) 2020-07-31
HRP20180060T1 (hr) 2018-02-23
MY192259A (en) 2022-08-12
UY35225A (es) 2014-07-31
EP3339303B9 (en) 2021-07-21
MA38175B1 (fr) 2018-11-30

Similar Documents

Publication Publication Date Title
HRP20201194T1 (hr) Laktami kondenzirani s arilom i heteroarilom
HK1207069A1 (en) Heterocyclic compounds and uses thereof
HK1206740A1 (en) Substituted hetero azepinones
HK1214820A1 (zh) 雜芳基吡啶酮和氮雜-吡啶酮酰胺化合物
EP2884134A4 (en) THERMOREGULATOR
SG11201500927YA (en) Kimono
EP2935226A4 (en) HETEROARYL COMPOUNDS AND USES THEREOF
ZA201503367B (en) Heteroaryl derivatives and uses thereof
HK1216017A1 (zh) 二唑內酰胺
SG11201403852UA (en) Fused pyrroledicarboxamides and their use as pharmaceuticals
EP2820499A4 (en) PROGRAMMABLE SENSORS
AU4710P (en) Fusion xTriticosecale
GB201215901D0 (en) Protein modification
GB201209803D0 (en) MK-V fusion system